Donidalorsen not checked

Ionis Pharmaceuticals, Inc. · ISIS 721744

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
6 in total · 3 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Donidalorsen will be administered by subcutaneous (SC) injection.”In the company’s words, NCT07298447 on ClinicalTrials.gov
Tested for
Hereditary Angioedema, Hereditary Angioedema (HAE)
Main trialPhase 3
“The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).”In the company’s words, NCT05392114 on ClinicalTrials.gov
Other names
ISIS 721744 · IONIS-PKK-LRx

Other drugs for Hereditary Angioedema

All 8 drugs for Hereditary Angioedema

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2026 A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Phase 3Recruiting Jun 2029 Donidalorsen Treatment in Children With Hereditary Angioedema
Phase 3Completed 9 Nov 2023 OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
Phase 2Completed 4 Jan 2021 A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Phase 2Completed 24 Jan 2025 An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
Phase 1Completed 9 Oct 2018 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Donidalorsen

Following is part of Solo: you see every change to Donidalorsen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in